News

The National Institute for Health and Care Excellence1h
Updated guideline to increase access to treatments for early-stage chronic heart failure could reduce deaths and hospital admissions by thousands
Based on the Office for National Statistics population and the NHS Quality and Outcomes framework 2023-24 around 614,000 adults in England have heart failure. Of these, around 63% (387,000) adults are ...
National Institute for Health and Care Excellence6d
Technology appraisal committee meeting (committee B)
The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to change. You will receive your ...
The National Institute for Health and Care Excellence6d
Fostering the digital health tech revolution
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS. These ...
National Institute for Health and Care Excellence17d
Guidance in topic selection
Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199] Medicine Awaiting decision TBC Ixekizumab for ...
National Institute for Health and Care Excellence18d
Nivolumab-relatlimab for Melanoma [TSID 12178]
Further information The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except ...
National Institute for Health and Care Excellence18d
Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]
Further information The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except ...
National Institute for Health and Care Excellence18d
Nifedipine - Lidocaine for Chronic Anal Fissure [TSID 12093]
Further information The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except ...
National Institute for Health and Care Excellence18d
Diltiazem (Anatop, SLV-324, VEN 307) for Anal fissure [TSID 12100]
Further information The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except ...
National Institute for Health and Care Excellence18d
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
The lives of thousands of people with chronic kidney disease could be changed for the better after NICE today (Friday, 23 May) recommended a new treatment option for use in the NHS. Just over 4,200 ...
National Institute for Health and Care Excellence19d
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...
National Institute for Health and Care Excellence19d
Information for the public
Dostarlimab (Jemperli) with platinum-based chemotherapy is available on the NHS. It is a possible treatment for when systemic treatment is suitable in adults with primary endometrial cancer that has ...